Does Larotrectinib Offer New Hope to Children With TRK Fusion-Positive Solid Tumors?
Because of the drug’s promising safety and efficacy, the first child was treated on trial only 9 months after the first adult with a TRK fusion was treated.
Pediatric Cancer
PEDIATRIC CANCER ADVISOR
FEATURED CONTENT
-
-
Recent Conference Highlights New Potential Targets for Pediatric Cancer Treatments
Advances in targeted therapy for pediatric patients were presented at the AACR Special Conference on Pediatric Cancer.
PEDIATRIC CANCER NEWS
Potential Unintended Consequences of the “Right to Try” Act on the Delivery of Palliative Care to Children With Cancer
“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
The Price Is Right for CAR-T in Pediatric Patients, Analysis Concludes
Vigorous Exercise Improved Life Expectancy for Adult Survivors of Childhood Cancers
Relative Survival for AYAs Comparable to General Population After 7 Years
Want to read more?
Please login or register first to view this content.
